Featured
September 01, 2015
< 3 of 65 >

bioMérieux - First-Half 2015 Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 28 under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the six months ended June 30, 2015. The Statutory Auditors had performed a review of the financial statements.

Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux delivered a solid performance in the first half of 2015, attesting to its effective positioning as a specialist in the in vitro diagnosis of infectious diseases. The strong dynamic observed during the past 6 months reflects our broad geographic footprint and our diversified portfolio of solutions, which was recently enhanced with the acquisition of BioFire in molecular biology. Against this backdrop, and despite the economic instability, we are confident in our ability to reach our 2015 objectives."

Download the Full Press Release